The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1475
Palbociclib (Ibrance) for Metastatic Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Palbociclib (Ibrance – Pfizer), an oral cyclin-dependent kinase inhibitor, has been approved by the FDA for use in combination with the aromatase inhibitor letrozole (Femara, and generics) for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. It is the first cyclin-dependent kinase inhibitor to become available in the US.

STANDARD TREATMENT — The American Society of Clinical Oncology (ASCO) recommends that postmenopausal women with ER-positive, HER2-negative metastatic breast cancer be offered hormone therapy (preferably an aromatase inhibitor) as standard first-line treatment.1,2 These patients often do well for many years with hormone therapy alone; how to identify a target population that could benefit from the addition of other drugs ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Palbociclib (Ibrance) for Metastatic Breast Cancer
Article code: 1475b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian